Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (688621.SS)

CNY 37.71

(-1.33%)

Market Cap (In CNY)

4.22 Billion

Revenue (In CNY)

932.12 Million

Net Income (In CNY)

184.75 Million

Avg. Volume

1.65 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
28.9-72.48
PE
-
EPS
-
Beta Value
0.206
ISIN
CNE100005139
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Yujing Liu
Employee Count
-
Website
https://www.sun-novo.com
Ipo Date
2021-06-21
Details
Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of chemical drugs and peptide drugs in China. The company offers small molecule chemical generic drugs; peptide products; and drugs for indications, such as impetigo, acne, renal anemia, chronic kidney disease dialysis patient hyper parathyroid hormone, analgesia, and other symptoms. It also provides packaging material compatibility test, impurity research, extract research, migration research, safety evaluation, and other research services; consistency evaluation services; clinical research services; registration consulting and agency services; and range of pharmacokinetics-pharmacodynamics and GLP bioanalysis services, including pharmacokinetic bioanalysis, immunogenic biology analysis, pharmacodynamics, and biomarker bioanalysis services. The company was founded in 2009 and is based in Beijing, China.